BioVendor Group®



Advancing Molecular Diagnostics

Product catalog

About BioVendor 3

PCR Assays 4
RealFast™ Assays 6
StripAssays® 9

NGS Assays 12
Microbiome 12
fastGEN 14
epicGEN 16
GENOVESA 18

About BioVendor

We are an international group of biotechnology companies with expertise in molecular diagnostics, immunodiagnostics, and radio-immunodiagnostics. Founded in 1992 in the Czech Republic, we have grown from a local company into a global innovator with in-house research, development, and production of in-vitro diagnostic (IVD) products, supported by an international distribution network.

Our strategy is anchored by three key projects – CLIA, MBA, and NGS – focusing our innovation and delivery across next-generation sequencing, chemiluminescent immunoassays, and Microblot-Array. By combining scientific excellence, strong innovation capacity, and a presence in more than 100 markets worldwide, we deliver solutions that advance laboratory practice and patient care, making us one of the key players in clinical diagnostics.

Our molecular portfolio covers RealFast™ Assays, StripAssays®, NGS assays based on fastGEN and epicGEN technologies, microbiome solution, and GENOVESA bioinformatics software for NGS data analysis and interpretation.

Meet the Molecular diagnostics team



Fabio Echeverry, PhD
Senior Area Sales Manager
echeverry@viennalab.com



Birgit Altenbacher, PhD
Head of Operational Marketing
altenbacher@viennalab.com



Iveta Tóthová, PhD
Senior Operational Product Manager
iveta.tothova@biovendor.com

PCR Assays

When focus beats volume

Real-time PCR remains a gold-standard technology for fast, targeted genetic analysis. It enables the amplification and simultaneous detection of specific DNA sequences in real time using fluorescent signals, delivering highly reliable results with minimal complexity.

Our PCR portfolio is designed for laboratories that require speed, precision, and ease of implementation, whether for routine testing or targeted mutation analysis.

Key benefits


- Fast, accurate and easy-to-handle workflows
- Ready-to-use reagents
- Seamless integration into routine laboratory workflow
- Reliable detection of known variants
- Suitable for copy number variation (CNV) analysis

Sample preparation

What matters before you get started?

Reliable results begin long before amplification. High-quality DNA input is a critical factor influencing the accuracy, sensitivity, and reproducibility of any PCR-based assay.

To support every step of your workflow, we offer flexible sample preparation solutions, from standard DNA extraction to streamlined direct-to-PCR approaches, allowing you to choose the method that best fits your laboratory setup and sample type.



Flexible solutions for every workflow

DNA extraction kits

Designed to deliver high-quality DNA suitable for downstream PCR applications, including solutions with IVDR certification.

Direct-to-PCR with D2PCR™ Buffer

An alternative approach that eliminates the need for DNA extraction from human peripheral whole blood anticoagulated with EDTA, significantly reducing hands-on time and turnaround time. Designed to be used in combination with RealFast™ Assays.

Skip extraction. Save time.


Reduce workflow time and simplify your routine testing with direct PCR, ideal for high-throughput or time-sensitive applications.

Sample preparation kits

Why choose our sample preparation solutions?

- Flexible workflows tailored to different laboratory needs
- Reduced hands-on time and operational complexity
- Reliable performance across various sample types

Area	REF	Product Name	Unit Size	Application	Regulatory Status
StripAssays® RealFast™ Assays	2-014	GENXTRACT™ Blood DNA Extraction System	100 Rxn	DNA extraction from fresh, frozen and dried blood	CE IVDR Class A
StripAssays® RealFast™ Assays	2-020	Spin Micro DNA Extraction Kit	20 Rxn	DNA extraction and purification from whole blood and buccal swabs	RUO
RealFast™ Assays	2-030	D2PCR™ Buffer	100 Rxn	For direct-to-PCR applications	CE IVDR Class A
NEW SMN1 RealFast™ Assays SCID-XLA mpx RealFast™ Assays HbS-HbC mpx RealFast™ Assays	2-050 2-052	quickDBS	100 Rxn 500 Rxn	DNA extraction from DBS (Dried Blood Spots) for immediate use in PCR with SMN1 RealFast™Assays, SCID-XLA mpx RealFast™Assays and HbS-HbC mpx RealFast™Assays	RUO



RealFast™ Assays

Ideal for targeted testing when speed and simplicity matter most.

RealFast™ Assays are designed for rapid and targeted detection of specific genetic markers using real-time PCR technology. Supporting both singleplex and multiplex formats, they provide a flexible solution for laboratories requiring fast, accurate, and cost-efficient analysis.


Whether you process a few samples or run high-throughput workflows, RealFast™ assays deliver consistent performance with minimal complexity.

Seamless workflow integration

RealFast™ Assays are fully compatible with our sample preparation solutions, including direct-to-PCR using D2PCR™ Buffer, enabling laboratories to significantly reduce turnaround time and increase efficiency.



Workflow



Key benefits

- High sensitivity and specificity
- From DNA to results in less than 90 minutes
- Ready-to-use reagents with minimal hands-on time
- Controls included for reliable performance
- Compatible with standard real-time PCR platforms

Validated cyclers

- Applied Biosystems 7500 Fast
- Applied Biosystems StepOne™
- LightCycler® 480 II (Roche)
- CFX96 and CFX Opus 96 (Bio-Rad)
- Rotor-Gene 6000 (Qiagen)
- QuantStudio™ 5 (Thermo Fisher Scientific)
- MIC qPCR Cycler (Bio Molecular Systems)

Sample requirements

- Low amount of starting DNA material
- Typically 2–10 ng/µl with adequate purity

Applications

- Identification of disease-associated mutations
- Detection of genetic polymorphisms (SNPs, CNVs)
- Pharmacogenetics testing
- Screening and confirmatory testing

ⓘ Trial kit

An attractive trial option is available together with application support, enabling smooth and efficient implementation in your laboratory workflow.

Single marker detection

Category	Clinical Topic	REF 100 / 32 Rxn	Product Name	Detail	Regulatory Status
NEW	Spinal Muscular Atrophy (SMA)	7-700 / --- 7-702 (500 Rxn)	SMN1 RealFast™ Assay	Detects *SMN1* c.840C which is used for SMA analysis	RUO
NEW	Cystic Fibrosis (CF)	7-260 / 7-263	CF F508del RealFast™ Assay	Detects the most common clinically relevant mutation (F508del) in the *CFTR* gene	CE IVDD
	Carbamazepine Hypersensitivity	7-640 / 7-643	HLA-A3101 RealFast™ Assay	Detects the human leukocyte antigen (HLA) *HLA-A*31:01* allele, which is strongly associated with carbamazepine hypersensitivity reactions in Europeans and Japanese	CE IVDD
	Carbamazepine Hypersensitivity	7-630 / 7-633	HLA-B1502 RealFast™ Assay	Detects the human leukocyte antigen (HLA) *HLA-B*15:02* allele, which is strongly associated with carbamazepine hypersensitivity reactions in Asian populations	CE IVDD
	Carbohydrate Intolerance	7-150 / 7-153	LCT -13910C>T RealFast™ Assay	Detects the most common polymorphism in the *lactase (LCT)* gene causing lactase non-persistence	CE IVDD
	Cardiovascular Diseases (CVD)	7-230 / 7-233	FGB -455G>A RealFast™ Assay	Identifies homozygosity for the -455G>A *fibrinogen beta-chain (FGB)* allele which may increase susceptibility to atherothrombosis in at-risk patients	CE IVDD
	CVD	7-110 / 7-113	FV Leiden RealFast™ Assay	Detects the most common genetic risk factor associated with venous thromboembolism, the 1691G>A mutation in the *Factor V (F5)* gene	CE IVDR
	CVD	7-240 / 7-243	FXII 46C>T RealFast™ Assay	Identifies patients with the unfavorable TT genotype for *Factor XII (F12)*, who may have an increased susceptibility to thrombotic disorders	CE IVDD
	CVD	7-250 / 7-253	FXIII V34L RealFast™ Assay	Identifies carriers of the protective 34L variant of Factor XIII (F13A) among at-risk patients of hereditary thrombophilia	CE IVDD
	CVD	7-160 / 7-163	MTHFR 677C>T RealFast™ Assay	Detects common mutation in the *methylenetetrahydrofolate reductase (MTHFR)* gene causing hyperhomocysteinemia, which is a risk factor for cardiovascular disease	CE IVDD
	CVD	7-170 / 7-173	MTHFR 1298A>C RealFast™ Assay	Detects common mutation in the *methylenetetrahydrofolate reductase (MTHFR)* gene causing hyperhomocysteinemia, which is a risk factor for cardiovascular disease	CE IVDD
	CVD	7-180 / 7-183	PAI-1 4G/5G RealFast™ Assay	Detects the 4G risk allele in the *SERPINE1* gene, encoding plasminogen activator inhibitor-1 (PAI-1), and is associated with cardiovascular disease and pregnancy complications	CE IVDD
	CVD	7-120 / 7-123	PTH 20210G>A RealFast™ Assay	Detects the second most important genetic risk factor for venous thromboembolism in the *Factor II* gene, encoding prothrombin (PTH)	CE IVDR
	Congenital Adrenal Hyperplasia (CAH)	7-410 / ---	CAH RealFast™ CNV Assay	Discriminates between deletions, duplications and normal copy number status of the *CYP21A2* gene in patients with CAH. Recommended to be used in combination with CAH StripAssay® [REF 4-380]	CE IVDR
	Genetic Predisposition	7-620 / 7-623	HLA-B27 RealFast™ Assay	Detects the human leukocyte antigen (HLA) *HLA-B*27* allele, which is associated with ankylosing spondylitis	CE IVDR
	Haemochromatosis	7-130 / 7-133	HFE C282Y RealFast™ Assay	Detects the common C282Y variant in the *HFE* gene causing hereditary haemochromatosis (HH) type 1	CE IVDR
	Haemochromatosis	7-140 / 7-143	HFE H63D RealFast™ Assay	Detects the common H63D variant in the *HFE* gene causing hereditary haemochromatosis (HH) type 1	CE IVDR
	Pharmacogenetics	7-420 / ---	CYP2D6 RealFast™ CNV Assay	Discriminates between deletions, duplications and normal copy number status of the *CYP2D6* gene. Recommended to be used in combination with PGX-CYP2D6 XL StripAssay®[REF 4-770]	CE IVDR

Genetic Disorder · Genetic Predisposition · Cancer · Pharmacogenetics · Microbiology

Category	Clinical Topic	REF 100 / 32 Rxn	Product Name	Detail	Regulatory Status
	Pharmacogenetics	7-610 / 7-613	HLA-B5701 RealFast™ Assay	Detects the human leukocyte antigen (HLA) *HLA-B*57:01* allele, which is associated with hypersensitivity to the anti-HIV drug abacavir	CE IVDD
	Pharmacogenetics	7-210 / 7-213	SLCO1B1 c.521T>C RealFast™ Assay	Detects a variant in human *solute carrier organic anion transporter family member 1B1 (SLCO1B1)* gene in patients who are at higher risk for developing statin-induced myopathy	CE IVDD
	Pharmacogenetics	7-190 / 7-193	VKORC1 -1639G>A RealFast™ Assay	Detects the most important polymorphism in the *Vitamin K Epoxide Reductase Complex 1 (VKORC1)* gene associated with interindividual dose requirements for oral anticoagulants	CE IVDD

Multiplex testing

Category	Clinical Topic	REF 100 / 32 Rxn	Product Name	Detail	Regulatory Status
NEW	Severe Combined Immunodeficiency (SCID)	7-710 / --- 7-712 (500 Rxn)	SCID-XLA mpx RealFast™ Assay	Allows for the simultaneous analysis of the copy number of T-cell receptor excision circles (TRECs) and kappa-deleting recombination excision circles (KRECs)	RUO
NEW	Sickle Cell Disease (SCD)	7-280	HbS-HbC mpx RealFast™ Assay	Allows for the simultaneous analysis of c.20A>T (HbS) and c.19G>A (HbC*)* mutation in the β-globin *(HBB)* gene	RUO
	CVD	7-115 / 7-118	FV-PTH mpx RealFast™ Assay	Simultaneous detection of the most important thrombophilic mutations 1691G>A in the *Factor V* gene and 20210G>A in the *Factor II* gene, encoding prothrombin (PTH)	CE IVDR
	CVD	7-165 / 7-168	MTHFR mpx RealFast™ Assay	Simultaneous detection of the two most common mutations in the *MTHFR* gene: 677C>T and 1298A>C	CE IVDD
	AAT deficiency/ COPD	7-265 / 7-268	AAT mpx RealFast™ Assay	Detects *S and *Z variants of the *SERPINA1* gene predisposing individuals to chronic obstructive pulmonary disease (COPD) and liver disease due to deficiency of alpha-1 antitrypsin (AAT)	CE IVDD
	Haemochromatosis	7-135 / 7-138	HFE mpx RealFast™ Assay	Simultaneous detection of the two most common mutations in the *HFE* gene: H63D and C282Y	CE IVDR
	Pharmacogenetics	7-225 / 7-228	CYP2C9 mpx RealFast™ Assay	Simultaneous detection of *CYP2C9 *2* (c.430C>T) and *CYP2C9 *3* (c.1075A>C) polymorphisms to determine the drug response of known targets, like S-warfarin or phenytoin	CE IVDD
	Service	CS-045	RealFast™ Confirmation Service	Service to assist in establishing RealFast™ Assays as well as for performance monitoring	

CE IVDR: CE-marked under Regulation (EU) 2017/746. Notified Body 0123. IVDD products remain under legacy status until December 2028.

Genetic Disorder | Genetic Predisposition | Cancer | Pharmacogenetics | Microbiology



Smart qPCR Data Interpretation

RealFast™ Plugins, powered by FastFinder™ enables automated and standardized interpretation of RealFast™ Assay results, streamlining qPCR data analysis and reducing hands-on evaluation time. Assay-specific algorithms support reliable result interpretation, minimize manual evaluation errors, and generate standardized reports.
For research use only.

StripAssays®


Analyze multiple mutations in a single assay.

StripAssays® bridge the gap between targeted PCR testing and more complex NGS approaches. Based on reverse hybridization of biotinylated PCR products to mutation-specific probes immobilized on a Teststrip, they enable the simultaneous detection of multiple genetic variants in a single assay.

This makes them an ideal solution when single-marker testing is not sufficient, but full-scale sequencing is not required.



Workflow



Key benefits

- Detection of multiple mutations in a single test (up to 48 alleles)
- Robust and reproducible methodology
- From sample to result in less than 6 hours
- Low instrument complexity
- Clear and straightforward result interpretation

Sample requirements

- Low amount of starting DNA material
- Typically 2–10 ng/µl with adequate purity

Flexible workflow options

Manual workflow
- Thermocycler
- Water bath with shaking platform
- Shaker

Automated workflow
- Automated instrument for Teststrip processing

Applications

- Detection of SNPs and InDels
- Pharmacogenetics markers
- Hereditary disorders testing

ⓘ Trial kit

An attractive trial option is available together with application support, enabling smooth and efficient implementation in your laboratory workflow.

Category	Clinical Topic	REF	Product Name	Unit Size	Detail	Regulatory Status
	Alzheimer Disease	4-280	Apo E StripAssay®	20 tests	Detection of isoforms Apo E2, E3 and E4	CE IVDD
	Cancer	5-560	BRAF 600/601 StripAssay®	20 tests	Ultra-sensitive detection of 9 *BRAF* mutations in codons 600 and 601	CE IVDD
	Cancer	5-630	EGFR XL StripAssay®	20 tests	Ultra-sensitive detection of 30 *EGFR* mutations in exons 18/19/20/21	CE IVDD
	Cancer	5-680	KRAS XL StripAssay®	20 tests	Ultra-sensitive detection of 29 *KRAS* mutations in codons 12/13/59/60/61/117/146	CE IVDD
	Cancer	5-620	NRAS XL StripAssay®	20 tests	Ultra-sensitive detection of 22 *NRAS* mutations in codons 12/13/59/60/61/146	CE IVDD
	Carbohydrate Intolerance	4-300	Lactose Intolerance StripAssay®	20 tests	Detection of two *lactase* gene polymorphisms -13910T>C and -22018A>G	CE IVDR
	Carbohydrate Intolerance	4-310	Sugar Intolerance StripAssay®	20 tests	Detection of two *lactase* gene polymorphisms and four *aldolase B* gene mutations	CE IVDR
	Cardiovascular Diseases (CVD)	4-240	CVD StripAssay®	20 tests	Testing for 12 genetic variants associated with cardiovascular diseases	CE IVDD
	CVD	4-370	CVD StripAssay® A	20 tests	Testing for 8 genetic variants predisposing to atherosclerosis	CE IVDD
	CVD	4-360	CVD StripAssay® T	20 tests	Testing for 9 genetic variants predisposing to venous thromboembolism	CE IVDR
	CVD	4-290	FV-PTH StripAssay®	20 tests	Detection of the *Factor V* Leiden and *Factor II,* encoding prothrombin (PTH), gene mutations	CE IVDD
	CVD	4-260	FV-PTH-MTHFR StripAssay®	20 tests	Detection of the *Factor V* Leiden, *Factor II*, encoding prothrombin (PTH), and *MTHFR* gene mutations	CE IVDD
	Congenital Adrenal Hyperplasia (CAH)	4-380	CAH StripAssay®	20 tests	Testing for 11 most prevalent *CYP21A2* mutations. Recommended to be used in combination with CAH RealFast™ CNV Assay [REF 7-410]	CE IVDR
	Cystic Fibrosis (CF)	4-410	CF StripAssay®	10 tests	Detection of 34 common *CFTR* mutations and the IVS8 variants 5T/7T/9T	CE IVDR
	CF	4-430	CF StripAssay® GER	10 tests	Detection of 31 common *CFTR* mutations	CE IVDR
	CF	4-420	CF StripAssay® TUR	10 tests	Detection of 24 common *CFTR* mutations and the IVS8 variants 5T/7T/9T	CE IVDR
	CF	4-440	CF StripAssay® EXT	10 tests	Detection of 38 common *CFTR* mutations and the IVS8 variants 5T/7T/9T	CE IVDR
	Familial Mediterranean Fever (FMF)	4-230	FMF StripAssay®	20 tests	Detection of 12 *MEFV* gene mutations	CE IVDR
	FMF	4-390	FMF-SAA1 StripAssay®	20 tests	Detection of 12 *MEFV* gene mutations and *SAA1* genotypes 1.1, 1.3 and 1.5	CE IVDR

Genetic Disorder · Genetic Predisposition · Cancer · Pharmacogenetics · Microbiology

Category	Clinical Topic	REF	Product Name	Unit Size	Detail	Regulatory Status
	Genetic Predisposition	4-320	HLA-B27 StripAssay®	20 tests	Detection of all disease-relevant *HLA-B*27* subtypes	CE IVDD
	Haemochromatosis	4-220	Haemochromatosis StripAssay® A	20 tests	Detection of 18 mutations: twelve *HFE* mutations, four *TFR2* mutations and two *FPN1* mutations	CE IVDR
	Haemochromatosis	4-210	Haemochromatosis StripAssay® B	20 tests	Detection of 3 *HFE* gene mutations: C282Y, H63D, S65C	CE IVDD
	Pharmacogenetics	4-780	PGX-5FU XL StripAssay®	20 tests	Detection of *DPYD* genetic variants HapB3, DPYD*13, DPYD*2A, p.D949V associated with toxicity of 5-fluorouracil therapy	CE IVDD
	Pharmacogenetics	4-750	PGX-CYP2C19 StripAssay®	20 tests	Testing for CYP2C19 variants *1, *2, *3, *4, *5, *6, *7, *8 and *17	CE IVDR
	Pharmacogenetics	4-770	PGX-CYP2D6 XL StripAssay®	20 tests	Testing for CYP2D6 variants *1 - *12, *14, *15*, *17, *29, *35, *39, *40, *41, *58, *114. Recommended to be used in combination with CYP2D6 RealFast™ CNV Assay [REF 7-420].	CE IVDR
	Pharmacogenetics	4-740	PGX-TPMT StripAssay®	20 tests	Testing for *TPMT* variants *1, *2, *3A, *3B and *3C associated with response to thiopurine therapy	CE IVDD
	Thalassemia	4-160	α-Globin StripAssay®	10 tests	Detection of 21 common α-Globin gene mutations	CE IVDR
	Thalassemia	4-130	β-Globin StripAssay® MED	20 tests	Detection of 22 mutations covering >90% of β-Globin defects found in Mediterranean countries	CE IVDR
	Thalassemia	4-140	β-Globin StripAssay® IME	20 tests	Detection of 22 mutations covering >90% of β-Globin defects found in the Middle East and India	CE IVDR
	Thalassemia	4-150	β-Globin StripAssay® SEA	20 tests	Detection of 22 mutations covering >90% of β-Globin defects found in Southeast Asia	CE IVDR
	Thalassemia	4-170	β-Thal Modifier StripAssay®	20 tests	Testing for 5 polymorphisms associated with severity of β-Thalassemia	CE IVDD
	Service	CS-042	StripAssay® Confirmation Service		Service to assist in establishing StripAssays® as well as for performance monitoring	
	StripAssays®	6-100	StripAssay® Evaluator		Software for automated scanning of teststrips, interpretation, and archiving of results	RUO

CE IVDR: CE-marked under Regulation (EU) 2017/746. Notified Body 0123. IVDD products remain under legacy status until December 2028.

Genetic Disorder | Genetic Predisposition | Cancer | Pharmacogenetics | Microbiology

NGS Assays

When insight goes further than single targets

Next-generation sequencing (NGS) is a powerful molecular technology that enables the simultaneous analysis of multiple genetic regions in a single run. By sequencing millions of DNA fragments in parallel, it provides comprehensive insights that go far beyond other approaches.

Our NGS portfolio is designed to support a wide range of applications from focused panels to more comprehensive genomic profiling while maintaining efficiency, flexibility, and ease of implementation.

Amplicon-based assays

Microbiome


Key features

- Simultaneous species-level identification of bacterial and fungal communities
- Input from 2.5 ng DNA
- No PhiX required
- Dedicated microbiome web tool (RUO) for data analysis
- Alpha and beta diversity analysis

Sequencer compatibility

- Illumina®
- Broader compatibility in development

Workflow



Gut speaks. We translate!

Gain more comprehensive view of the human gut microbiome. Our solution analyzes both the 16S rRNA gene and the ITS2 region of fungal DNA, providing a more comprehensive view of the human gut microbiome.

Category	REF	Product Name	Unit Size	Detail	Regulatory Status
	9-131-16	16S Microbiome + ITS NGS Assay [16 rxn]	16 Rxn	Targeted amplification of the bacterial V3-V4 variable regions of the 16S rRNA gene and the fungal ITS2 region. Includes bioinformatics analysis and report generation for species-level classification of the human gut microbiome.	RUO
	9-131	16S Microbiome + ITS NGS Assay [Set A]	96 Rxn	Differs from [Set B] and [Set C] in indexing primers only. Multiplexing up to 288 samples.	RUO
	9-132	16S Microbiome + ITS NGS Assay [Set B]	96 Rxn	Differs from [Set A] and [Set C] in indexing primers only. Multiplexing up to 288 samples.	RUO
	9-133	16S Microbiome + ITS NGS Assay [Set C]	96 Rxn	Differs from [Set A] and [Set B] in indexing primers only. Multiplexing up to 288 samples.	RUO



Genetic Disorder | Genetic Predisposition | Cancer | Pharmacogenetics | Microbiology

fastGEN

Designed for targeted sequencing when precision and confidence are critical.


fastGEN is an amplicon-based NGS solution designed for ultra-deep sequencing of clinically relevant targets. It enables reliable detection of low-frequency variants, even in challenging sample types, while maintaining a fast and streamlined workflow.



Key features

- Ultra-deep sequencing for low-frequency variant detection
- High precision and consistency
- Optimized for challenging samples, including FFPE and ctDNA
- Fast and efficient workflow
- Minimal input DNA requirements


One-step PCR library preparation workflow



1 Samples + Master Mixes

2 Real-time PCR amplification

3 Pooling of indexed amplicons



4 Pool purification

5 Pool dilution + denaturation

6 Sequencing

Sample compatibility

- DNA isolated from tumor tissue
- DNA isolated from FFPE samples
- Circulating tumor DNA (ctDNA) from blood

Applications

- Targeted oncology profiling
- Detection of low-frequency variants
- Hereditary predisposition analysis

Sequencer compatibility

- Illumina®
- Element Biosciences™ (AVITI)
- GeneMind
- MGI Tech (with conversion kit)

Integrated data analysis

With every fastGEN kit, you have access to GENOVESA (RUO), our bioinformatics solution that streamlines data processing from raw sequencing data to clear and interpretable results.

Category	REF	Product Name	Unit Size	Detail	Regulatory status
	RDNGS0001	fastGEN SOLID Cancer Kit	16 Rxn	*NRAS, KRAS*: codons 12, 13, 59, 60, 61, 117 and 146; *BRAF*: codon 600	CE IVDD
	RDNGS0002	fastGEN LUNG Cancer Kit	16 Rxn	*EGFR*: exons 18, 19, 20 and 21	CE IVDD
	RDNGS0007	fastGEN PIK3CA Cancer Kit	16 Rxn	*PIK3CA*: exons 2, 3, 5, 7, 8, 10, 14 and 21	RUO
	RDNGS0008	fastGEN TERT Cancer Kit	16 Rxn	*TERT*: promotor and mutations C228T and C250T	RUO
	RDNGS0009 RDNGS0009-32	fastGEN TP53 Cancer Kit	16 Rxn 32 Rxn	*TP53:* exons 2-11, 2 non-canonical exons (between exon 9 and 10) and adjacent introns (min 6nt)	RUO
	RDNGS0010	fastGEN POLE/CTNNB1 Cancer Kit	16 Rxn	*POLE*: exons 9, 11, 13 and 14 *CTNNB1*: exons 3, 7 and 8	RUO
	RDNGS0011	fastGEN BCR::ABL1 Cancer Kit	16 Rxn	*BCR::ABL1*: major and minor breakpoint	RUO
	RDNGS0016	fastGEN H3F3A/IDH1/2 Cancer Kit	16 Rxn	*IDH1*: codon 132 *IDH2:* codons 140 and 172 *H3F3A:* codons 28 and 35	RUO
	RDNGS0018	fastGEN Food Intolerance Kit	16 Rxn	*ALDOB1*: rs118204429, rs387906225, rs1800546, rs76917243, rs78340951, rs77718928, rs370793608, rs764826805 *AOC1*: rs10156191, rs1049742, rs2268999, rs1049793, rs2052129 *MCM6*: rs4988235, rs182549	RUO
	RDNGS0019	fastGEN MSI Kit	16 Rxn	12 relevant loci for MSI status evaluation	RUO
	RDNGS0024	fastGEN EGFR/HER2 II Cancer Kit	16 Rxn	*EGFR*: exons 18, 19, 20 and 21 *HER2:* exons 7, 8, 17, 19, 20 and 21	RUO
	RDNGS0021	fastGEN MPN Cancer Kit	16 Rxn	*CALR:* exon 9 *JAK2:* exons 12, 13, 14, 16 *MPL:* exons 4, 10, 12	RUO
	RDNGS1001	fastGEN SOLID II Cancer Kit	16 Rxn	*NRAS, KRAS*: codons 12, 13, 59, 60, 61, 117 and 146 *BRAF*: codons 594-609	RUO
	RDNGS0022	fastGEN Crohn's & Celiac Disease Kit	16 Rxn	*NOD2:* rs2066844, rs2066845, rs5743293 *IL23R:* rs1004819 and rs10889677 HLA-DQ2.2: rs2395182, rs7775228, rs4713586 HLA-DQ2.5: rs2187668 HLA-DQ8: rs7454108	RUO

Genetic Disorder · Genetic Predisposition · Cancer · Pharmacogenetics · Microbiology

Hybrid capture-based assays

epicGEN


Comprehensive genomic analysis made simple.

epicGEN is a hybrid capture-based NGS solution designed for comprehensive genomic profiling. It enables analysis beyond predefined hotspots, providing broader coverage and deeper insight into genetic alterations.

Key features

- Hybrid capture technology for extended genomic coverage
- MSI analysis included*
- Flexible DNA input range (1–1000 ng)
- Suitable for challenging samples, including FFPE
- Tailored panel design

Workflow



Applications

- Comprehensive oncology profiling
- Detection of a wide range of variant types
- MSI status assessment*

Sequencer compatibility

- Illumina®
- Element Biosciences™ (AVITI)
- GeneMind
- MGI Tech

* Applicable to epicGEN Solid Cancer & MSI Kit and Hereditary Cancer NGS Assay

Integrated data analysis

With every epicGEN kit, you have access to GENOVESA (RUO), our bioinformatics solution that streamlines data processing from raw sequencing data to clear and interpretable results.

Category	REF	Product Name	Unit Size	Detail	Regulatory Status
	RDEG0001-32	epicGEN Solid Cancer & MSI Kit	32 Rxn (4x8 Rxn)	All relevant regions of 44 genes and 13 MSI loci	RUO
	9-221	Hereditary Cancer NGS Assay	16 Rxn	Targeting the whole CDS of 31 genes. Allows analysis of SNVs, InDels, and CNVs of the covered genes (e.g. *BRCA1, BRCA2, CDH1,...*).	RUO
	9-231	Somatic Mutations NGS Assay	16 Rxn	Targeting the whole CDS of genes covered. Analysis of SNVs and InDels in 10 genes (e.g. *BRAF, EGFR, KRAS*, ...) and fusions in 3 genes (i.e. *ALK, RET, ROS1*).	RUO

Genetic Disorder | Genetic Predisposition | Cancer | Pharmacogenetics | Microbiology



GENOVESA


From FASTQ to report. Simplified.

GENOVESA is our integrated bioinformatics solution designed to transform raw sequencing data into clear, actionable results. It streamlines the entire data analysis process, from primary data processing to variant interpretation, through an intuitive and user-friendly interface.

For research use only.

Key features

- End-to-end analysis from FASTQ to final report
- Intuitive interface designed for routine laboratory use
- Predefined pipelines optimized for fastGEN and epicGEN kits
- Fast and reliable variant interpretation
- Secure data processing on dedicated in-house servers
- Supports analysis of third-party NGS data



No bioinformatics expertise required.

Focus on results, not data processing.

Why GENOVESA?

- No need for complex bioinformatics infrastructure
- Reduced analysis time and hands-on effort
- Standardized and reproducible results
- Clear and actionable outputs for confident decision-making

Functionalities

- InDel detection
- CNV analysis
- RNA fusion and aberrant splicing isoform detection
- MSI, TMB and HRD analysis
- Integrated database
- Customizable filtering
- Automated reporting

Applications

- Somatic and germline variant analysis
- Genotyping
- RNA sequencing (RNA-seq)
- Metagenomics
- Whole exome sequencing (WES)
- Whole genome sequencing (WGS)
- Viral genomics

REF	Product Name	Detail	Regulatory Status
PLC1_Genovesa	GENOVESA software	Analysis of amplicons, panels, CES, WES, and WGS	RUO

For more information, please contact us at productsupport.moldx@biovendor.com

DISTRIBUTED BY

Distributor logo
to be inserted here.

Distributor contact details
to be inserted here.

MANUFACTURER

ViennaLab Diagnostics GmbH
Gaudenzdorfer Guertel 43-45
A-1120 Vienna, Austria
+43 1 812 0156
marketing@viennalab.com
www.viennalab.com

BioVendor – Laboratorní medicína s.r.o.
Karásek 1767/1
621 00 Brno
Czech Republic
www.biovendor.com

V112026
EN ISO 13485